Rivaroxaban beats Lovenox: RECORD4 trial

15 June 2008

Results from a pivotal Phase III trial presented at the annual meeting of the European Federation of National Associations of Orthopedics & Traumatology, in Nice, France, demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior to enoxaparin in preventing venous blood clots in patients who underwent total knee replacement surgery.

The head-to-head study compared the agent with the US-approved dosing regimen for Sanofi-Aventis' Lovenox (enoxaparin), the current standard-of-care. Rivaroxaban is being jointly developed by US health care major Johnson & Johnson and Germany's Bayer HealthCare.

The RECORD4 data show that rivaroxaban (10mg once-daily) provided TKR surgery patients a statistically-significant 31% relative risk reduction in total venous thromboembolism events - defined in the study as the composite of all deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality - compared to enoxaparin (30mg twice-daily; 6.9% and 10.1%, respectively, p=0.012). Rates of major bleeding, the main safety endpoint, were greater in rivaroxaban-treated patients. This difference was not statistically significant from the rate of major bleeding in enoxaparin-treated patients (p=0.110).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight